HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Marketing: EllaOne, Sudocrem And Vitabiotics Get Social

Executive Summary

Highlighting the latest social-media activity by some of the UK's biggest consumer health brands, including HRA Pharma's EllaOne, Teva's Sudocrem and Vitabiotics WellKid.

You may also be interested in...



HRA Educating Young Britons About Emergency Contraception

Over half of the UK's Generation Z have no idea how emergency contraption works. HRA Pharma is looking to change this with its Fact Not Fiction PR campaign for EllaOne.

HRA Pharma ‘Breaks The Stigma’ Of Emergency Contraception With EllaOne Podcast

By talking "candidly" about the morning after pill in a new EllaOne podcast, HRA Pharma wants to demonstrate that there is “nothing to be embarrassed about” when it comes to emergency contraception.

Alliance Pharma Targeting M&A To Grow OTC Portfolio

UK-based Alliance Pharma is currently looking at deals - large and small - to expand its consumer health portfolio in its existing markets, including the US and Europe.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel